154 results on '"Beyar Katz, Ofrat"'
Search Results
2. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies
3. Lymphoma pseudoprogression observed on [18F]FDG PET-CT scan 15 days after CAR-T infusion
4. Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients after Allogeneic HCT or CD19-based CART therapy—A Single-Center Prospective Cohort Study
5. Early Antibiotic Deescalation and Discontinuation in Patients with Febrile Neutropenia after Cellular Therapy: A Single-Center Prospective Unblinded Randomized Trial
6. Cytomegalovirus colitis presenting with lower gastrointestinal bleeding following chimeric antigen receptor‐T cell therapy.
7. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
8. The Clinical Spectrum of Hepatic Manifestations in Chronic Lymphocytic Leukemia
9. Response rates of extra‐nodal diffuse large B cell lymphoma to anti‐CD19‐CAR T cells: A real word retrospective multicenter study
10. Data from Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy
11. Supplementary Data from Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy
12. Advances in chimeric antigen receptor T cells
13. Supplemental Figures from Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
14. Data from Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
15. Supplemental Figures S1-S6 from Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
16. Supplementary Materials and Methods from Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
17. Supplemental Table S1 from Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
18. Early antibiotic de-escalation and discontinuation in Patients with Febrile Neutropenia after Cellular Therapy: A Single Center Prospective Unblinded Randomized Trial
19. Adult Nephrotic Syndrome after Hematopoietic Stem Cell Transplantation: Renal Pathology is the Best Predictor of Response to Therapy
20. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to anti CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
21. Response Rates of Extra-Nodal Diffuse Large B Cell Lymphoma to CD19-CAR T Cells - a Real Word Retrospective Multi-Center Study
22. G-CSF Mobilized Apheresis As an Alternative Source of CAR T-Cells
23. Peripheral T‐cell lymphoma mimicking Schnitzler syndrome
24. Immunogenicity of a Third Dose of the BNT162b2 mRNA Covid-19 Vaccine in Patients with Impaired B Cell Reconstitution After Cellular Therapy—A Single Center Prospective Cohort Study
25. A Comprehensive Toxicity and Efficacy Analysis of Different Bridging Therapies Prior to Anti CD19-CAR-T Cell Therapy in Patients with DLBCL- a National Multi-Center Cohort Study
26. Antibiotic Stewardship in Patients after Cellular Therapy with Febrile Neutropenia- a Single Center Prospective Unblinded Randomized Trial
27. Sequential Therapy with Fitcy Preparative Regimen for Patients with Primary Refractory AML - a Single Center Retrospective Analysis
28. Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells
29. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies
30. CNS Prophylaxis in Diffuse Large B-Cell Lymphoma: A Common Toxic Clinical Practice Based on Abundant Opinion, Despite Evidence Suggesting Futility
31. Second Vs Third Line Treatment with Axicabtagene Ciloleucel for Large B Cell Lymphoma - a Real-Life National Multicenter Retrospective Cohort Study with Propensity Score Matching
32. [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies.
33. Characteristics and recognition of early infections in patients treated with commercial anti‐CD19 CAR‐T cells.
34. Proinflammatory Macrophages Promote Multiple Myeloma Resistance to Bortezomib Therapy
35. Daratumumab for eradication of minimal residual disease in high-risk advanced relapse of T-cell/CD19/CD22-negative acute lymphoblastic leukemia
36. Superior outcome of patients with favorable-risk acute myeloid leukemia using consolidation with autologous stem cell transplantation
37. Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse
38. Novel Approaches to Acute Myeloid Leukemia Immunotherapy
39. Published abstracts at international meetings often over- or underestimate the initial response rate
40. DA- EPOCH- R Treatment Can Cause Adrenal Insufficiency in Non-Hodgkin Lymphoma Patients
41. Therapy-Educated Mesenchymal Stem Cells Enrich for Tumor-Initiating Cells
42. Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer
43. Anti-herpesvirus prophylaxis versus placebo, no treatment or pre-emptive treatment in hemato-oncological malignancies
44. Autologous Stem Cell Transplantation in Favorable Acute Myeloid Leukemia Is Associated with a Better Long-Term Prognosis: a Single Center Experience
45. Autoinflammatory associated vasculitis
46. Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy
47. Peripheral T-cell lymphoma mimicking Schnitzler syndrome
48. Bortezomib-induced pro-inflammatory macrophages as a potential factor limiting anti-tumour efficacy
49. Should autotransplantation in acute myeloid leukemia in first complete remission be revisited?
50. Analysis of the Stromal Cellular Components of the Solid Tumor Microenvironment Using Flow Cytometry
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.